Status:
COMPLETED
Comparing the Effects of Different Doses of Dexamethasone to Treat Inpatient COVID-19
Lead Sponsor:
University of Oklahoma
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This open label clinical trial is to evaluate two different doses of dexamethasone on the health outcome using World Health Organization ordinal scale at day 28 in hospitalized patients with COVID-19.
Detailed Description
The coronavirus disease 2019 (COVID-19) pandemic is a serious global health threat. Multiple antiviral or immunomodulatory therapies have failed to show any mortality benefit for patients with COVID-1...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old
- RT-PCR confirmed COVID-19 infection
- Positive pressure ventilation (non-invasive or invasive) or high flow nasal cannula (HFNC) or need supplemental oxygen with oxygen mask or nasal cannula
Exclusion
- Underlying disease requiring chronic corticosteroids
- Severe adverse events before admission, i.e. cardiac arrest;
- Contraindication for corticosteroids;
- Death is deemed to be imminent and inevitable during the next 24 hours
- Recruited in other clinical intervention trial
- Pregnancy
- Patient on judicial protection
Key Trial Info
Start Date :
January 21 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 4 2022
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT04707534
Start Date
January 21 2021
End Date
March 4 2022
Last Update
March 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Oklahoma Medical Center
Oklahoma City, Oklahoma, United States, 73104